Received Nov 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE) | SANOFI PASTEUR | UNK | — | OT |
sensitivities to flu vaccines with having a rash; Initial information received on 21-Nov-2025 regarding an unsolicited valid non-serious case received from a patient. This case involves an unknown age female patient who was sensitivities to flu vaccines with having a rash after receiving influenza USP TRIVAL A-B high dose subvirion vaccine [Fluzone HD]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received an unknown dose of influenza USP TRIVAL A-B high dose subvirion vaccine Suspension for injection in pre-filled syringe (strength, expiry date and lot number not reported) via unknown route in unknown administration site for Immunization. Information on the batch number was requested corresponding to the one at time of event occurrence. On an unknown date the patient was sensitivities to flu vaccines with having a rash (rash) (latency- 3 to 5 days after the injection). It was reported that, "Flublok is the same as the Fluzone by Sanofi; caller wanting to know what are the differences; and wanting to know if FLUBLOK is an mRNA vaccine. The rash would appear 3 to 5 days after the injections. Caller only mentioned the wording FLUZONE." Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event. At time of reporting, the outcome was Unknown for the event.